SCHEMBL3532871

SCHEMBL3532871

c1ccc(COn2ncc3ccccc32)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.53
TSHR P16473 3/20 0.41
ALDH1A1 P00352 2/20 0.41
KMO O15229 1/20 0.41
KMT2A Q03164 6/20 0.40
HPGD P15428 3/20 0.40
NPSR1 Q6W5P4 2/20 0.40
MEN1 O00255 2/20 0.40
ASAH1 Q13510 1/20 0.39
CYP1A2 P05177 2/20 0.38
ALOX15 P16050 1/20 0.38
MAPT P10636 2/20 0.38
POLB P06746 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
ADRA2A P08913 1/20 0.36
ALOX5 P09917 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4955320 0.83 HTR2A (0.46) RECQLTSHRALDH1A1KMT2AHPGD
SCHEMBL4953481 0.82 CNR1 (0.40) RECQLALDH1A1MAPTRAB9AALOX5
SCHEMBL4949569 0.80 GPR35 (0.40) RECQLKMT2AHPGDNPSR1MEN1
SCHEMBL4952937 0.80 RECQL (0.36) RECQLTSHRALDH1A1KMT2AHPGD
SCHEMBL3534557 0.79 RECQL (0.43) RECQLTSHRALDH1A1KMOKMT2A
SCHEMBL31661043 0.79 RECQL (0.43) RECQLTSHRALDH1A1KMOKMT2A
SCHEMBL16393961 0.78 HCAR3 (0.43) KMT2AMEN1NPC1RAB9A
SCHEMBL5316072 0.78 RECQL (0.37) RECQLTSHRALDH1A1MAPTRAB9A
SCHEMBL4954075 0.76 ALDH1A1 (0.36) RECQLTSHRALDH1A1KMT2AHPGD
SCHEMBL4956158 0.76 DHFR (0.39) RECQLTSHRALDH1A1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102558231-B Ophthalmic compositions for treating ocular hypertension MERCK & CO INC 2015-05-27 CN disclosed
CN-102558231-A Ophthalmic compositions for treating ocular hypertension MERCK & CO INC 2012-07-11 CN disclosed
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
EP-1663987-B1 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION MERCK & CO INC (US) 2009-03-18 EP disclosed
US-7410992-B2 Ophthalmic compositions for treating ocular hypertension MERCK & CO. INC. (US) 2008-08-12 US disclosed
US-20070010491-A1 Ophthalmic compositions for treating ocular hypertension MERCK SHARP & DOHME LLC 2007-01-11 US disclosed
CN-1845904-A Ophthalmic composition for treating ocular hypertension MERCK & CO INC (US) 2006-10-11 CN disclosed
US-7064215-B2 Indazole benzimidazole compounds CHIRON CORPORATION (US) 2006-06-20 US disclosed
EP-1663987-A1 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION Merck & Co., Inc. (US) 2006-06-07 EP disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed
WO-2005026128-A1 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION MERCK & CO., INC. (US) 2005-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010491-A1 Ophthalmic compositions for treating ocular hypertension REN, KCNH2, KCNH3 RECQL 1638/4885TSHR 1299/4885ALDH1A1 1431/4885
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK RECQL 4291/4885TSHR 4110/4885ALDH1A1 1562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.